Iteos Therapeutics Inc Company Overview

Iteos Therapeutics Inc logo
Iteos Therapeutics Inc
Iteos Therapeutics Inc primary media

About Iteos Therapeutics Inc

Iteos Therapeutics (NASDAQ:ITOS) is a biotechnology firm focused on the discovery, development, and commercialization of novel cancer immunotherapies. Its aim is to revolutionize cancer treatment by developing therapies that harness the body's immune system to fight cancer more effectively. The company's pipeline includes innovative candidates targeting the adenosine pathway and other immune checkpoint pathways, designed to address a wide range of tumors. By prioritizing patient-centered research, Iteos Therapeutics seeks to advance the scientific understanding of cancer immunotherapy and bring new treatments to market that improve the lives of those facing this challenging disease.

What is Iteos Therapeutics Inc known for?

Snapshot

2011
Year founded
167
Employees
Massachusetts, United States
Head office
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Iteos Therapeutics Inc

  • EOS-448: An immune-targeting IgG1 antibody designed to enhance the immune system's ability to fight cancer.
  • EOS-850: Aimed at inhibiting the Adenosine A2A Receptor, potentially blocking a pathway cancer cells use to evade the immune system.
  • EOS-200271: An early-stage program focusing on undisclosed targets within the immune-oncology space, intended to modulate immune system components for cancer treatment.
  • Collaboration with GSK: Joint development of anti-cancer therapies, leveraging proprietary technologies and research capabilities.
  • Partnership with Merck: Focused on evaluating the combination of EOS-448 with pembrolizumab, Merck's anti-PD-1 therapy, in various cancer types.

equipe executiva do Iteos Therapeutics Inc

  • Dr. Michel Detheux Ph.D.President, CEO & Director
  • Mr. Matthew A. Call M.B.A.Chief Operating Officer
  • Dr. David Feltquate M.D., Ph.D.Chief Medical Officer
  • Mr. Matthew GallChief Financial Officer
  • Dr. Yvonne McGrath Ph.D.Chief Scientific Officer
  • Ms. Adi OsovskyExecutive Vice President of Legal
  • Mr. Philippe BrantegemChief People Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.